ADC Therapeutics Amends Royalty Agreement for Enhanced Strategic Flexibility and Growth Potential

ADC Therapeutics Restructures Royalty Agreement for Strategic Flexibility

ADC Therapeutics SA redefines its financial landscape with a significant amendment to its royalty purchase agreement with HealthCare Royalty. This alteration lowers the financial burden associated with a potential change of control, reducing the buyout obligation from $750 million to $150 million if a change occurs before December 31, 2027, and to $200 million thereafter. The revised agreement also maintains HealthCare Royalty's entitlement to royalties on product sales until the original royalty cap is met. The intent behind this adjustment appears to bolster ADC Therapeutics' strategic maneuverability, especially as the company anticipates a surge in growth linked to its flagship therapy, ZYNLONTA.

Ameet Mallik, CEO of ADC Therapeutics, expresses confidence in the projected trajectory for ZYNLONTA, underpinned by an expanding evidence base and several critical data readouts scheduled for this year. With expectations of meaningful revenue growth anticipated to begin in 2027, ADC foresees peak U.S. revenues ranging between $600 million and $1 billion annually, contingent on regulatory approvals and inclusion in medical compendia. This outlook aligns with HealthCare Royalty's optimism regarding emerging clinical data related to diffuse large B-cell lymphoma and indolent lymphomas, suggesting a collaborative future driven by shared interests.

The agreement also grants HealthCare Royalty warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81, valid until December 31, 2030, with a lock-up period extending through the end of 2027. This amendment is framed as mutually beneficial, reinforcing both companies' commitment to advancing therapeutic innovation while realizing the market potential of ADC Therapeutics' growing portfolio. By enhancing strategic flexibility, ADC Therapeutics positions itself favorably to navigate potential corporate transitions while also ensuring continued investment from HealthCare Royalty.

In related developments, the amended deal aligns with ADC’s broader strategy of maximizing its clinical offerings and adaptability within the dynamic oncology market. The emphasis on ZYNLONTA's growth potential serves as a testament to the company’s commitment to pioneering antibody drug conjugates that meet unmet medical needs.

The collaborative framework established through the revised agreement underscores the importance of investment partnerships in fostering innovation in the life sciences sector. As ADC Therapeutics continues to enhance its operational capabilities and clinical outlook, the move emphasizes the growing necessity for flexible financial arrangements that support sustained growth and market engagement.